Kurwanya kanseri y'umwijima hakoreshejwe uburyo bwa Bioocus GPC3 CAR-T Therapy

Amavuriro y'umurwayi

Pawan, umuntu w’umwihariko ukomoka mu Buhinde, yasanzwemo indwara y’umwijima idakira yagoranye kubera kanseri y’umwijima (HCC) muri Kanama 2024. Ku myaka 67 ubwo yasuzumwaga (yujuje imyaka 68 mu gihe cyo kuvurwa), yahuye n’indwara ikomeye irimo ibisebe byinshi mu mwijima, ibimenyetso bya kanseri byo hejuru nka AFP na PIVKA-II, kubura amaraso, imikorere mibi ya enzymes z’umwijima, ndetse no kugabanuka kw’amagufwa nyuma yaho. Nubwo yanyuze mu nzira ya radioembolization (TARE), transarterial chemoembolization (TACE), immunotherapy (Atezolizumab + Bevacizumab, Tremelimumab + Durvalumab), n’ubuvuzi bwihariye (Lenvatinib, Cabozantinib, Regorafenib), indwara ye yarakomeje. Ibipimo bya genetiki byagaragaje impinduka muri TP53, KRAS, CDKN2A, CTNNB1, na ARID1A, hamwe n’imyitwarire mike ya PD-L1 n’uburangare bwa HRD, bigaragaza ko hari uburyo budahagije bwo gusubiza ku buryo busanzwe imiti imwe n’imwe igabanya ubukana bw’indwara. Mu gushaka ibisubizo bigezweho, Pawan yoherejwe mu bitaro bya Tianjin Cancer Hospital binyuze muri Bioocus kugira ngo ahabwe ubuvuzi bwacu bwa GPC3 CAR-T ku buvuzi bufite nimero P1544.

Urugendo rw'Ubuvuzi

Ubuvuzi bwa Pawan bwa CAR-T bwatangiye na leukapheresis ku ya 11 Kanama 2025, bukurikirwa no gukorwa no guterwa ku ya 2 Nzeri 2025. Yahawe dose ya 4.73 × 10^8 CAR-T selile, yibasira GPC3, ikimenyetso cyagaragaye cyane muri HCC. Mbere yo guterwa harimo fludarabine na cyclophosphamide kugira ngo byongere imbaraga zo gutera. Nyuma yo guterwa, amaraso ye yo mu gice cy’imbere yakurikiranwe kugira ngo CAR-T yongereke ku minsi ya 4 (D4), 7 (D7), 10 (D10), na 12 (D12).

• D4 (Ku ya 6 Nzeri 2025):Uturemangingo twa CAR-T turi kuri 5.15% bya CD3+ T cells (agaciro kabyo ni 9.27 × 10^6/L), bigaragaza ko habanje gushyirwamo uturemangingo.
• D7 (Ku ya 9 Nzeri 2025):Yageze ku kigero cya 3.97% (6.12 × 10^7/L), igaragaza ko ikwirakwira ry’ibinyabutabire rikora.
• D10 (Ku ya 12 Nzeri 2025):04% (9.07 × 10^6/L).
• D12 (Ku ya 14 Nzeri 2025):Ihamye kuri 2.82% (2.26 × 10^7/L), aho uturemangingo twa T twose turi kuri 5.4 × 10^9/L, CD3+ kuri 14.87%, uturemangingo twa T twa CD8+ twinshi turi kuri 77.88%, hamwe n’utundi duce twa CAR-T turinganiye (urugero, 2.46% CD8+CARGPC3+/CD8+).

Ubwo yajyanwaga mu bitaro kuva ku ya 11 Kanama kugeza ku ya 15 Nzeri 2025, Pawan yagize ingaruka mbi nke, harimo umuriro muke (kugeza kuri 38.5°C), umunaniro, no kwiyongera kwa enzymes z'umwijima by'igihe gito, byafashwe neza nta ndwara ikomeye yo gusohora cytokine (CRS grade 1) cyangwa uburozi bw'ubwonko. Ibimenyetso by'ingenzi byakomeje kugaragara, kandi ubuvuzi bushyigikira bwarimo imiti igabanya ubwandu, imirire, no gukurikirana ingorane nka ascites.

Ibisubizo by'indashyikirwa

Nubwo kwaguka kwa CAR-T ari guke, byagaragaje ko bikomeza kandi birwanya ikibyimba, bifitanye isano n'ibimenyetso bya kanseri bihamye kandi nta ntambwe ihita iterwa mu isuzuma ry'ibizamini. Urubanza rwa Pawan rujyanye n'intsinzi ya Bioocus muri GPC3 CAR-T kuri HCC, aho no kwihangana ku rugero ruto bishobora gutuma abarwayi badashobora kwihanganira indwara bakira indwara. Yasezerewe mu bitaro ari muzima ku ya 15 Nzeri 2025, hamwe n'inama zo gukomeza gukurikirana, harimo ibimenyetso bya kanseri, imikorere y'umwijima, na PET-CT scan. Ubu buryo bwo kuvura bwagabanyije uburozi bw'umubiri mu gihe bukemura ikibazo cy'umwijima w'ikibyimba.